Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 17, 2007

Cepheid and bioMerieux Partner on Sepsis Test

  • Cepheid and bioMerieux will together develop and commercialize an innovative line of sepsis test products on the GeneXpert® platform.

    The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. There is also the potential for hospital-acquired pneumonia applications. 

    Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive, worldwide basis.

    In addition, bioMerieux has granted Cepheid a nonexclusive, worldwide license under the Hiramatsu patents on methicillin-resistant staphylococcus aureus (MRSA) for all applications. Cepheid will continue to develop, manufacture, and market MRSA products.

  • You’re all set! Thank you for subscribing to GEN Highlights.